Male Hypogonadism Market by Therapy (Testosterone Replacement therapy and Gonadotropin and Gonadotropin-Releasing Hormones Therapy

Male hypogonadism is a medical condition characterized by the inability of the testes to produce sufficient amount of testosterone, which is responsible for the development of secondary sexual characteristics. This results in underdevelopment of muscles, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.

View Sample Copy of Report @ https://goo.gl/nOpFFu

The global male hypogonadism market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, growing at a CAGR of 3.1% during the analysis period. Globally, the prevalence for hypogonadism among men is on a rise at a rapid rate, and according to multiple studies, only 10–15% of patients receive treatment for this condition. Major factors that drive the market growth include high incidence of hypogonadism; rise in geriatric population; growth in awareness of hypogonadism & its treatment options; and increased risk of developing hypogonadism due to increased incidence of chronic lifestyle diseases such as diabetes and obesity. In March 2015, FDA issued cautions & warnings against use of testosterone products as a therapy, and ordered the manufacturers to change labels & add cautions on their packaging. From recent studies conducted by the FDA, there is a high risk of acquiring cardiovascular diseases due to the use of TRT, thus impeding the market growth during the forecast period. However, novel treatment options that are under developmental stage have shown positive results in terms of efficacy, and they are expected to have lesser or no side effects. Therefore, these advancements are anticipated to provide new opportunities in the future.

Enquire here @ https://goo.gl/fGEvsP

The global male hypogonadism market is segmented based on therapy, drug delivery, type, and geography. Based on therapy, it is bifurcated into testosterone replacement therapy (TRT), and gonadotropin and gonadotropin-releasing hormones therapy. Gonadotropin and gonadotropin-releasing hormones therapy is further sub-classified into LH, FSH, human chorionic gonadotropin (hCG), and GnRH. Based on drug delivery, it is classified into topical gels, injectables, transdermal patches, and others. Based on type, it is categorized into Klinefelter's syndrome, Kallmann syndrome, pituitary disorders, and others. Based on geography, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).

MALE HYPOGONADISM MARKET KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market, with current trends and future estimations to elucidate the imminent investment pockets.
It presents a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis by therapy helps in understanding the various types of therapies used for the treatment of hypogonadism.
Comprehensive analysis of geographical regions is provided, which helps in determining the prevailing opportunities in these geographies.
Key players within the market are profiled and their strategies are analyzed thoroughly to determine competitive outlook of the global market.
MALE HYPOGONADISM MARKET KEY MARKET SEGMENTS

BY THERAPY

Testosterone Replacement Therapy
Gonadotropin and Gonadotropin-Releasing Hormones Therapy
Luteinizing Hormone (LH)
Follicle-Stimulating Hormone (FSH)
Human Chorionic Gonadotropin (hCG)
Gonadotropin-Releasing Hormone (GnRH)
BY DRUG DELIVERY

Topical Gels
Injectables
Transdermal Patches
Others
BY TYPE

Klinefelter's Syndrome
Kallmann Syndrome
Pituitary Disorders
Others
BY GEOGRAPHY

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Rest of Europe
Asia-Pacific
Japan
India
China
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa
LIST OF KEY PLAYERS PROFILED IN THE REPORT

AbbVie Inc.
Allergan plc
Astrazeneca plc
Bayer AG.
Eli Lilly and Company Ltd.
Endo International plc.
Merck & Co., Inc.
Ferring
Finox Biotech
IBSA Institut Biochimque SA
Laboratoires Genevrier
Teva Pharmaceutical Industries Ltd.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

Lipocine Inc.
Pfizer Inc.
Aytu Biosciences
Diurnal Group PLC
Hyundai Pharmaceuticals Co Ltd.
Perrigo Company plc
Novus Biologicals, LLC

For Complete Analysis & Puchase Enquire on Male Hypogonadism Market @ http://www.bigmarketresearch.com/request-for-customization/905690

Contact us:
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
Direct : + 1-503-894-6022
Toll Free : + 1-800-910-6452
Email: help@bigmarketresearch.com
Web: http://www.bigmarketresearch.com

With the arsenal of different search reports, we help you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

5933 NE Win Sivers Drive, #205

This release was published on openPR.